1. Introduction
Intravenous (IV) cannulation is a common procedure for drug and fluid administration. In this procedure, an IV cannula is inserted into a patient’s vein to enable drug and fluid administration as well as blood sampling. The cannula must remain in the patient’s vein throughout the IV infusion. If the cannula is displaced from the patient’s vein during the infusion, then the medication will be infused into the surrounding tissue. This phenomenon is called extravasation and results in complications.
Figure 1a displays a schematic of a typical IV cannulation procedure. An adhesive Tegaderm film is used to fix the cannula to prevent it being dislodged from the vein.
Extravasation injury refers to the damage resulting from vesicant medication leakage into surrounding tissue. This results in swelling of the skin around the cannulation site, as illustrated in
Figure 1b. Various factors contribute to the occurrence of extravasation. One factor is the small size and fragile nature of veins in infants and older patients, respectively. Another group of patients at risk of extravasation are those undergoing chemotherapy; these patients have compromised veins due to frequent venipunctures. Another factor is the movement of patients during IV infusion. This movement can lead to accidental displacement of the cannula from the vein [
1]. The incidence of extravasation in patients undergoing chemotherapy and newborns is approximately 0.1–0.6% [
2] and 11% [
3], respectively.
The severity of extravasation injuries depends on the type, concentration, and volume of the drug that was extravasated into the tissue layer. Vesicant medication refers to solutions with a pH of <5.5 or >8.5 or solutions with osmolarity > 290 mOsmol/L [
4,
5,
6]. Vesicant drugs result in severe tissue damage and adverse events because these drugs possess DNA binding ability; they can also kill replication cells that come into contact with them or cause vascular dilation. The volume of extravasated drug fluid in the tissue space depends on the infusion rate and the time that elapses from extravasation occurrence to detection by nursing staff [
7]. The severity of extravasation injury can vary from mild effects (e.g., redness, pain, and blistering) to critical conditions such as tissue necrosis, which requires surgical intervention such as debridement, skin grafting, or amputation. Patients with impaired levels of consciousness, neonates, and young children cannot alert nursing staff if they experience pain from extravasation. Therefore, extravasation detection is often delayed, which can result in severe injuries because of the continuous accumulation of fluid in subcutaneous tissue. Approximately 4% of neonates with extravasation injuries develop cosmetic or functional scars [
7] and 0.38% develop tissue necrosis [
8]. Therefore, early extravasation detection is critical for facilitating prompt medical intervention to minimize tissue damage.
Changes in various tissue parameters, such as tissue permittivity, permeability, temperature, impedance, blood flow rate, and blister formation [
9,
10,
11,
12,
13,
14,
15,
16,
17], are used as extravasation indicators. Current extravasation detection tools, such as the MEDRAD extravasation detection system (MEDRAD XDS) [
9,
10] and extravasation detection accessory (EDA) systems [
11,
12,
13], are mainly employed in computed tomography (CT). In the MEDRAD XDS, radio frequency waves are used for the detection of fluid accumulation under patients’ skin. Fluid pooling of volume less than 20 mL can be detected during CT. An EDA extravasation detection system, comprising an electrode patch with an embedded sensor, is included in the Empower CTA+ Injector System. The EDA system measures the change in skin impedance as an indicator of extravasation. The injection of fluid is paused by EDA systems if a clinically significant variation is detected. However, EDA systems are useful only at high flow rates of >2.5 mL/s, with an average detectable volume of 12.5 mL in the subcutaneous tissue. Both MEDRAD XDS and EDA equipment can detect large volumes (>12.5 mL) of extravasation but are not sufficiently sensitive to detect extravasation at an early stage. Moreover, both MEDRAD XDS and EDA systems are bulky, expensive, and unsuitable for routine use for numerous patients. Thus, the development of a portable and cost-effective device for detecting extravasation during routine IV cannulation is critical.
Bicen et al. presented various sensing modalities for extravasation applications given an infusion flow rate of 2 mL/min [
9]. The bioresistance and bioreactance modality exhibited low detection probability of approximately 0.5 and 0.66 for infusion volumes 2 and 5 mL, respectively. The detection probability was higher for infusion volumes >10 mL. The detection probability of the skin strain sensing modality was >0.9 and 0.87 for infusion volumes 2 and 5 mL, respectively.
The current study proposes piezoresistive sensor patches for early detection of extravasation for as little as 2 mL of infused fluid and with a minimum resistance change of 40%. The sensor patch is attached to the cannula site, and its resistance changes if a bump forms under the skin. This procedure aids early detection of extravasation and minimizes the severity of tissue injury. Sensor design details as well as testing results of ex vivo, in vivo, and clinical trial data are presented in the following sections.
2. Design Concept
Wearable sensor development for various medical and wellness applications is a growing trend. Examples of such sensors include skin patches for epidermal vital sign monitoring systems and wound monitoring [
18,
19,
20,
21,
22,
23,
24]. In the current study, a novel sensor patch system is proposed for the early detection of extravasation. The sensor patch system consists of two main components, namely a disposable sensor patch and a reusable external circuit reader (
Figure 2a,b). In the disposable sensor patch, 3M Tegaderm film (length: 10 cm; width: 6 cm) is used as the base adhesive substrate and a piezoresistive sensing electrode is deposited over this substrate. The sensing electrode has a serpentine pattern with sensing area 3.9 cm × 1.7 cm (
Figure 2a). The position of the sensing electrode is such that it covers the region surrounding the tip of the cannula where skin swelling due to extravasation is most likely to occur. Compared with a simple linear sensor shape design that is one-dimensional, the two-dimensional serpentine design covers a larger sensing region and results in higher detection sensitivity. The sensing electrode is patterned using two piezoresistive sensitive materials, namely gold and carbon conductive inks. The sensing electrode is then electrically connected through a conductive cable to the external circuit module. As per standard IV cannulation procedure, a Tegaderm film is directly placed over the cannula to secure the cannula. The sensor patch is placed over the Tegaderm film (
Figure 2c,d). The sensing patch has wide detection coverage over the hand of the patient and the sensing patch does not come into direct contact with the skin surface. Thus, no additional IV cannulation steps are required for the nursing staff when applying this sensor patch.
When extravasation occurs, the accumulation of drug in subcutaneous tissue results in swelling under the skin. The sensor patch on the skin surface is then stretched, as illustrated in
Figure 1b. This stretching results in sensing element deformation and changes the sensing electrode’s resistance. An external circuit module can be used to record this sudden change in the sensing electrode’s resistance and trigger an alert to the nursing staff for their immediate intervention. A member of the nursing staff can then inspect the cannula site and intervene. Therefore, early extravasation detection is critical for management of extravasation injury and prevention of adverse tissue damage.
3. Fabrication and Microassembly
The fabrication of the gold-based sensing patch involved a one-layer semiconductor process (
Figure 3). A stainless-steel stencil with sensor electrode pattern was fabricated through laser machining. This stencil functioned as the shadow mask for the gold metal evaporation process. Tegaderm films functioned as the base substrate for sensor patches and were attached to an 8-inch silicon carrier wafer followed by the stencil mask. A thin 200 Å titanium layer was first evaporated onto the Tegaderm film to act as an adhesion layer for the gold layer. Subsequently, a 2000 Å gold layer was evaporated on top of the titanium layer. The shadow mask was then detached from the Tegaderm films to form the sensing electrode pattern. A disadvantage of this process is the manufacturing cost. Because of the limited chamber size of the evaporator machine, the machine was able to process only approximately 40 sensor patches per run. This method results in considerable cost of manufacturing the sensor patch and means that gold is a relatively unattractive material for the sensing electrode.
To address the high cost of fabricating gold-based sensor patches, patches of an alternative cost-effective piezoresistive material, carbon conductive ink, were also investigated. The fabrication of the carbon-based sensor patches involved screen printing (
Figure 4), which is a panel-level process in which multiple Tegaderm films can be aligned and attached to the panel substrate in each process run. Approximately 100 sensor patches can be processed per process run. Furthermore, screen printing is faster than the evaporation process. The greater throughput and shorter processing time result in considerably more cost-effective sensor patch fabrication.
After sensing electrode patterning was conducted using commercially available carbon conductive ink (MOS Corporation, China), electrical cables were formed using copper wires, insulating tubing and a two-pin header. Electrical cables were assembled onto the bonding pads of the sensor patch. An additional adhesive film was used to secure the electrical cable to the sensor patch.
Figure 5 displays the assembled sensor patches with the gold-based and carbon conductive ink–based sensor electrodes.
5. Conclusions
This study presented gold- and carbon-based sensing patches. These sensor patches can be applied to patients to prevent extravasation injuries. The sensor patches can be attached to the skin in a similar manner as an adhesive film dressing to secure the cannula as part of the standard IV cannulation procedure. The performance of the sensor patches was validated through in vivo animal models and a clinical trial.
Animal trial was conducted on a piglet model to validate the performance of the sensor patches and evaluate the effect of false negative scenarios. The developed patches detected the skin swelling caused by extravasation. No false negative results were detected for 2 mL infusion volume. The gold-based sensing patch exhibited high sensitivity for extravasation detection at 2 mL fluid infusion volume.
Human trials were successfully conducted with nine volunteers and using the gold-based sensing patch. Extravasation injury conditions were simulated using cannulation in the subcutaneous tissue and infusion of 2 mL of normal saline solution at an infusion rate of 50 mL/h. The size of the extravasation bump was 0–4.2 mm, and the measured resistance change was 41–197%. The criterion for early detection was defined as a minimum 40% change in the sensing electrode’s resistance at 2 mL infused solution. The current results revealed that the sensor patch could detect extravasation at 2 mL infused volume for all participants. No false negative results were detected for an infusion volume of 2 mL. The gold-based sensor patch was validated using a negative control test condition and normal IV cannulation. On injection of 5 mL of normal saline into the volunteers’ veins, no change was observed in the bump height (H = 0 mm), and the measured resistance change was negligible (0.01%). A third testing condition was used to validate the resistance change caused by hand movement. The result revealed that the resistance change fluctuation due to movement differed from that due to extravasation. Thus, false positives caused by hand movements can be averted. The human trial demonstrated the functionality and ability of the gold-based sensing patch in early detection of extravasation for fluid volume of 2 mL in subcutaneous tissue.
The developed carbon-based sensing patch can address the high cost and low-throughput fabrication concerns faced with gold-based sensing patches. In ex vivo testing using pork knuckle, the gold- and carbon-based sensing patches exhibited comparable performance. The carbon-based sensing patch could detect 2 mL of extravasated fluid with an average resistance change of 51%. Thus, carbon is a potential alternative sensing material for extravasation detection because of its excellent performance, high-throughput manufacturing process, and cost-effectiveness. In future studies, the performance of carbon-based sensing patches can be validated in an actual clinical trial setting with patients.